Kingdon Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Kingdon Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-40,000	Closed	-$2.49M	–	161
2015 Q1	$2.49M	Buy	+40,000	New	+$2.33M	0.11%	132
2014 Q3	–	Sell	-200,000	Closed	-$10.5M	–	189
2014 Q2	$10.5M	Buy	+200,000	New	+$10.2M	0.4%	76
2013 Q3	–	Sell	-100,000	Closed	-$3.92M	–	220
2013 Q2	$3.92M	Buy	+100,000	New	+$3.89M	0.23%	115

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Kingdon Capital Management's TEVA Position: Q2 2015 in Review

Kingdon Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 40,000 shares — an estimated $2.49M sold.

Kingdon Capital Management first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $10.5M in Q2 2014. 819 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

Kingdon Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Kingdon Capital Management sold 40,000 Teva Pharmaceuticals shares in Q2 2015, an estimated $2.49M.
Kingdon Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Kingdon Capital Management's Teva Pharmaceuticals position peaked at $10.5M in Q2 2014.
819 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Kingdon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.